Researchers from the University of Sydney and the Liverpool School of Tropical Medicine have identified a promising and affordable new approach to counteracting the devastating effects of cobra venom. Their study shows that heparin, a widely used and inexpensive anticoagulant drug, can block key venom toxins from binding to human cells, thereby preventing necrosis—the severe and often irreversible tissue destruction commonly caused by cobra bites.

Cobra venom is particularly dangerous because it contains cytotoxins that rapidly attack cells at the bite site, leading to extensive local damage. While conventional antivenoms can be effective at preventing death, they often fail to stop this localized tissue injury, which can result in amputations, permanent disability, or long-term disfigurement. The newly identified approach targets this critical gap in current snakebite treatment.

According to the researchers, heparin works by acting as a molecular “decoy.” Instead of allowing venom toxins to attach to human cell membranes, heparin attracts and binds to the toxins first. This prevents them from interacting with tissue and triggering cell death. Laboratory experiments conducted on human cells, as well as tests in mouse models, demonstrated that heparin significantly reduced venom-induced tissue damage.

The findings are particularly important for low- and middle-income countries, where cobra bites are most common and access to advanced medical facilities is often limited. In many rural regions, delays in reaching hospitals mean that patients suffer severe local damage even if antivenom is eventually administered. A low-cost, widely accessible drug that can be given early could dramatically improve outcomes for snakebite victims.

Snakebites remain a major global health challenge. According to the World Health Organization, venomous snakebites kill up to 138,000 people every year and leave hundreds of thousands more with permanent physical disabilities. Cobras are among the most dangerous species due to the potency of their venom and their prevalence in densely populated areas across Asia and Africa.

One of the most significant advantages of this discovery is that heparin is already listed by the World Health Organization as an essential medicine and is widely available in hospitals around the world. This means that, if future clinical trials in humans confirm its safety and effectiveness for this new use, deployment could be rapid and cost-effective compared to developing entirely new antivenom therapies.

The researchers caution that heparin is not a replacement for antivenom but could serve as an important complementary treatment, particularly for preventing local tissue damage when administered soon after a bite. Further clinical studies will be needed to determine optimal dosing, safety, and effectiveness in human patients bitten by cobras.

Experts in tropical medicine note that this discovery represents a significant step forward in snakebite research. By repurposing an existing drug, scientists may be able to improve treatment outcomes for one of the world’s most neglected tropical health threats, especially in vulnerable communities with limited healthcare access.